CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases interest costs but extends financing flexibility.

The refinancing news and portfolio reshaping helped lift the share price, with a 1-day share price return of 6.26%. However, this follows weaker momentum, including a 30-day share price return down 4.12% and a 1-year total shareholder return down 37.49%.

If this kind of medical technology story has your attention, it can be useful to see what else is moving in related areas and uncover 40 healthcare AI stocks

With the stock down sharply over 1 and 3 years, yet trading at roughly a 55% discount to one intrinsic value estimate and below the average analyst price target, you have to ask: is this a reset opportunity, or is the market already baking in future growth?

Most Popular Narrative: 27.4% Undervalued

With CONMED's last close at $35.13 against a narrative fair value of $48.40, the valuation gap is clear and the narrative hangs on a specific earnings and margin path.

Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it.

The limited adjustments to long term growth and P/E assumptions suggest confidence that CONMED can broadly stick to its current execution path without requiring a major reset of expectations.

Want to see the blueprint behind that $48.40 fair value? The narrative leans on steadier revenue progress, higher margins, and a future earnings multiple that is more restrained than many peers. The mix of growth, profitability and discount rate assumptions is all laid out in detail. The tension is how much of that path the market believes today.

Result: Fair Value of $48.40 (UNDERVALUED)

However, you also have to weigh execution risk. Ongoing supply chain pressures and rising competition are both capable of undermining the earnings and margin path behind that fair value.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Conflicted by the mix of pressure and potential in the story so far? Take a closer look at the data, form your own view, and weigh up the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you may miss other opportunities, so use the screener to compare, filter, and build a stronger list of ideas.

• Spot potential value opportunities early by scanning 47 high quality undervalued stocks, where pricing and quality line up in a way that may merit a closer look.
• Prioritize resilience by checking 65 resilient stocks with low risk scores so you can focus on companies that may better match a steadier risk profile.
• Hunt for under-the-radar potential by reviewing the screener containing 22 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.